Pulmonary vascular diseases

References

• Hirani N, Brunner NW, Kapasi A, CCS/CTS Pulmonary Hypertension Committee, et al. Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. Can J Cardiol. 2020;36(7):977–992. doi:10.1016/j.cjca.2019.11.041.
   PubMed Web of Science ®Google Scholar
• Weatherald J, Boucly A, Chemla D, et al. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation. 2018;137(7):693–704. doi:10.1161/CIRCULATIONAHA.117.029254.
   PubMed Web of Science ®Google Scholar
• Kapasi A, Mehta S. Changing face of pulmonary arterial hypertension in Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2017;1(4):242–252. doi:10.1080/24745332.2017.1379366.
   Web of Science ®Google Scholar
• Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017;50(4):1700465. doi:10.1183/13993003.00465-2017.
   Web of Science ®Google Scholar
• Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019;156(2):323–337. doi:10.1016/j.chest.2019.02.004.
   PubMed Web of Science ®Google Scholar
• Chin KM, Sitbon O, Doelberg M, et al. Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. [Internet]. In: B27. UP-to-Date Pah Assessment and Management. American Thoracic Society; 2020 [cited 2020 Dec 15]. p. A2928–A2928. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928. doi:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928.
   Google Scholar
• Actelion. The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study [Internet]. clinicaltrials.gov.; 2020. [cited 2020 Dec 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02558231.
   Google Scholar
• White RJ, Jerjes-Sanchez C, Bohns Meyer GM, FREEDOM-EV Investigators, et al. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2020;201(6):707–717. doi:10.1164/rccm.201908-1640OC.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914. PMID: 30545980; PMCID: PMC6351338. doi:10.1183/13993003.01914-2018.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Thompson AAR, Billings CG, et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J. Jan 2020;55(6):2000041. doi:10.1183/13993003.00041-2020.
   Web of Science ®Google Scholar
• Hoeper MM, Pausch C, Grunig E, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant. 2020;39(12):1435–1444. Epub 2020 Sep 30. PMID: 33082079. doi:10.1016/j.healun.2020.09.011.
   PubMed Web of Science ®Google Scholar
• Zelt JGE, Hossain A, Sun LY, et al. Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension. J Heart Lung Transplant. 2020;39(7):675–685. doi:10.1016/j.healun.2020.03.026.
   Web of Science ®Google Scholar
• Gupta S, Batt J, Bourbeau J, et al. Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge: Key Highlights From the Canadian Thoracic Society (CTS) Position Statement. Chest. 2020;158(6):2270–2274. doi:10.1016/j.chest.2020.07.018.
   Web of Science ®Google Scholar
• Gupta S, Batt J, Bourbeau J, et al. Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2020;4(4):214–225. doi:10.1080/24745332.2020.1769436.
   Web of Science ®Google Scholar
• Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175–4181. doi:10.1093/eurheartj/ehx257.
   PubMed Web of Science ®Google Scholar
• Weatherald J, Boucly A, Launay D, et al. Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. Eur Respir J. 2018;52(4):1800678. doi:10.1183/13993003.00678-2018.
   Web of Science ®Google Scholar
• Weatherald J, Montani D, Sitbon O. 2020. Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. In: Bhatt S. (eds) Cardiac Considerations in Chronic Lung Disease. Respiratory Medicine. Humana. Cham: Springer/Humana Press. doi:10.1007/978-3-030-43435-9_6.
   Google Scholar
• Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med. 2021;384(4):325–334. doi:10.1056/NEJMoa2008470.
   PubMed Web of Science ®Google Scholar
• COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Internet]. https://coronavirus.jhu.edu/map.html. [cited 2020 Dec 10]
   Google Scholar
• Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559–1561. doi:10.1111/jth.14849.
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013.
   PubMed Web of Science ®Google Scholar
• Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002. doi:10.1111/jth.14888.
   PubMed Web of Science ®Google Scholar
• Jiménez D, García-Sanchez A, Rali P, et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. CHEST. 2021;159(3):1182–1196. doi:10.1016/j.chest.2020.11.005.
   Google Scholar
• Bansal A, Singh AD, Jain V, et al. The association of D-dimers with mortality, intensive care unit admission or acute respiratory distress syndrome in patients hospitalized with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Heart Lung. 2021;50(1):9–12. doi:10.1016/j.hrtlng.2020.08.024.
   Web of Science ®Google Scholar
• Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76(1):122–124. doi:10.1016/j.jacc.2020.05.001.
   PubMed Web of Science ®Google Scholar
• Moores LK, Tritschler T, Brosnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020;158(3):1143–1163. doi:10.1016/j.chest.2020.05.559.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) [Internet]. clinicaltrials.gov; 2020 [cited 2020 Dec 18]. Available from https://www.clinicaltrials.gov/ct2/show/NCT04372589.
   Google Scholar
• Kearon C, de Wit K, Parpia S, et al. Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability. N Engl J Med. 2019;381(22):2125–2134. doi:10.1056/NEJMoa1909159.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, Hokusai VTE Cancer Investigators, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378(7):615–624. doi:10.1056/NEJMoa1711948.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi:10.1200/JCO.2018.78.8034.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599–1607. doi:10.1056/NEJMoa1915103.
   PubMed Web of Science ®Google Scholar
• Mehta S, Helmersen D, Provencher S, Canadian Thoracic Society Canadian Respiratory Guidelines Committee, et al. Diagnostic Evaluation and Management of Chronic Thromboembolic Pulmonary hypertension: a clinical practice guideline. Can Respir J. 2010;17(6):301–334. doi:10.1155/2010/704258.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Dorfmuller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160112. doi:10.1183/16000617.0112-2016.
   PubMed Web of Science ®Google Scholar
• Helmersen D, Provencher S, Hirsch AM, et al. Diagnosis of Chronic Thromboembolic Pulmonary Hypertension: A Canadian Thoracic Society Clinical Practice Guideline Update. Canadian. Journal of Respiratory, Critical Care and Sleep Medicine. 2019;3(4):177–198. doi:10.1080/24745332.2019.1631663.
   Web of Science ®Google Scholar
• Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1):1801915. doi:10.1183/13993003.01915-2018.
   PubMed Web of Science ®Google Scholar
• Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an International Prospective Registry. Circulation. 2016;133(9):859–871. doi:10.1161/CIRCULATIONAHA.115.016522.
   PubMed Web of Science ®Google Scholar
• Aoki T, Sugimura K, Tatebe S, et al. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. Eur Heart J. 2017;38(42):3152–3159. doi:10.1093/eurheartj/ehx530.
   Web of Science ®Google Scholar
• Taniguchi Y, Jais X, Jevnikar M, et al. Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2019;38(8):833–842. doi:10.1016/j.healun.2019.04.006.
   Web of Science ®Google Scholar
• Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017;49(2):1601792. doi:10.1183/13993003.01792-2016.
   PubMed Web of Science ®Google Scholar
• Barco S, Klok FA, Konstantinides SV, et al. Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. J Thromb Haemost. 2020; 18(1):151–161. doi:10.1111/jth.14629.
   Web of Science ®Google Scholar
• Boon GJAM, van Rein N, Bogaard HJ, et al. Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. PLoS One. 2020;15(4):e0232354. doi:10.1371/journal.pone.0232354.
   PubMed Web of Science ®Google Scholar
• Jevnikar M, Montani D, Savale L, et al. Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. Eur Respir J. 2021;57(1):2002208. Epub ahead of print. PMID: 32675214 doi:10.1183/13993003.02208-2020.
   Web of Science ®Google Scholar
• Sena S, Bulent M, Derya K, et al. Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study. Pulm Circ. 2020;10(1):2045894019873545Published 2020 Feb 19. doi:10.1177/2045894019873545.
   Web of Science ®Google Scholar
• Bunclark K, Newnham M, Chiu YD, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2020;18(1):114–122. Epub 2019 Oct 18. doi:10.1111/jth.14649.
   PubMed Web of Science ®Google Scholar
• Jin Q, Zhao ZH, Luo Q, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: State of the art. World J Clin Cases. 2020;8(13):2679–2702. doi:10.12998/wjcc.v8.i13.2679.
   PubMed Web of Science ®Google Scholar
• Khan MS, Amin E, Memon MM, et al. Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2019; 291:134–139. [PMID:30850238 doi:10.1016/j.ijcard.2019.02.051].
   Web of Science ®Google Scholar
• Zoppellaro G, Badawy MR, Squizzato A, Denas G, Tarantini G, Pengo V. Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension - A Systematic Review and Meta-Analysis. Circ J. 2019;83(8):1660–1667. doi:10.1253/circj.CJ-19-0161.
   Web of Science ®Google Scholar
• Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003;76(5):1457–1464. doi:10.1016/s0003-4975(03)00828-2.
   PubMed Web of Science ®Google Scholar
• Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy. Circulation. 2009;120(13):1248–1254. doi:10.1161/CIRCULATIONAHA.109.865881.
   PubMed Web of Science ®Google Scholar
• Castro MA, Piloto B, Dos Santos Fernandes CJC, et al. Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. PLoS One. 2020;15(5):e0233063. doi:10.1371/journal.pone.0233063.
   Web of Science ®Google Scholar
• Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018.
   PubMed Web of Science ®Google Scholar
• van Thor MCJ, Snijder RJ, Kelder JC, et al. Does combination therapy work in chronic thromboembolic pulmonary hypertension? Int J Cardiol Heart Vasc. 2020;29:100544. eCollection 2020 Aug. doi:10.1016/j.ijcha.2020.100544.
   Web of Science ®Google Scholar